Rani Therapeutics Holdings (RANI) Change in Account Payables (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Change in Account Payables of $549000.0 for Q1 2026, up 240.99% year-over-year from $161000.0 in Q1 2025, and up 125.44% quarter-over-quarter from -$2.2 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Change in Account Payables (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Change in Account Payables history runs 7 years deep, the most recent figure standing at $549000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 240.99% year-over-year to $549000.0; the TTM figure through Mar 2026 stood at -$662000.0 (down 192.72% YoY), while the FY2025 annual figure was -$1.0 million, down 247.68% from the prior year.
- Change in Account Payables for Q1 2026 stood at $549000.0, up from -$2.2 million in the prior quarter.
- The five-year high for Change in Account Payables was $1.1 million in Q3 2024, with the low at -$2.2 million in Q4 2025.
- The 5-year median for Change in Account Payables is $131000.0 (2022), against an average of -$13058.8.
- The sharpest annual moves came in 2022 and 2025: Change in Account Payables jumped 263.89% in 2022, then sank 942.51% in 2025.
- Rani Therapeutics Holdings' Change in Account Payables stood at -$214000.0 in 2022, then sank by 209.81% to -$663000.0 in 2023, then soared by 68.78% to -$207000.0 in 2024, then tumbled by 942.51% to -$2.2 million in 2025, then soared by 125.44% to $549000.0 in 2026.
- Business Quant data shows RANI's Change in Account Payables at $549000.0 in Q1 2026, -$2.2 million in Q4 2025, and $669000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | -204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -204,000.00 |
| Jun 30, 2026 | -204,000.00 |
| Mar 31, 2026 | 549,000.00 |
| Mar 31, 2026 | 549,000.00 |
| Dec 31, 2025 | -2.16 Mn |
| Dec 31, 2025 | -2.16 Mn |
| Sep 30, 2025 | 669,000.00 |
| Sep 30, 2025 | 669,000.00 |
| Jun 30, 2025 | 278,000.00 |
| Jun 30, 2025 | 278,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | -207,000.00 |
| Dec 31, 2024 | -207,000.00 |
| Sep 30, 2024 | 1.06 Mn |
| Sep 30, 2024 | 1.06 Mn |
| Jun 30, 2024 | -300,000.00 |
| Jun 30, 2024 | -300,000.00 |
| Mar 31, 2024 | 158,000.00 |
| Mar 31, 2024 | 158,000.00 |